Synlogic and Roche amend collaboration; IBD option deadline extended to Jan 15, 2024 or later

SYNLOGIC, INC.

Roche holds exclusive option to negotiate a license for Synlogic's IBD Synthetic Biotic medicine.
Amendment extends option deadline to later of Jan 15, 2024 or 90 days after data delivery.
Original collaboration agreement effective June 16, 2021; amendment executed August 16, 2023.
Synlogic to deliver certain research data before the 90-day extension trigger.
No other changes to collaboration terms were disclosed.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SYNLOGIC, INC. amended Amendment to Pilot Collaboration and Option Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (effective 2023-08-16).

Action: amendment
Agreement: collaboration
Counterparty: F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
Effective: 2023-08-16

Exact text from the filing

On August 16, 2023, Synlogic Operating Company, Inc. (“Synlogic OpCo”), a wholly-owned subsidiary of Synlogic, Inc. (the “Company”), F. Hoffmann-La Roche Ltd (“Roche Basel”) and Hoffmann-La Roche Inc. (“Roche US”, and together with Roche Basel, “Roche”) entered into an amendment (the “Amendment”) to the Pilot Collaboration and Option Agreement (the “Roche Collaboration and Option Agreement”), effective as of June 16, 2021, by and between Synlogic OpCo and Roche.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

SYNLOGIC, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-214303

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.